Cabaletta Bio Q4 2023 Earnings Report $2.75 +0.04 (+1.48%) (As of 12/17/2024 05:56 PM ET) Earnings HistoryForecast Cabaletta Bio EPS ResultsActual EPS-$0.46Consensus EPS -$0.39Beat/MissMissed by -$0.07One Year Ago EPSN/ACabaletta Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACabaletta Bio Announcement DetailsQuarterQ4 2023Date3/21/2024TimeN/AConference Call ResourcesPress ReleaseCABA Earnings HistoryPowered by This Crypto Is Set to Explode in December (Ad)Discover our #1 crypto for the Trump Presidency Bull Run now! (Available for a Short Time) We highly recommend this hot altcoin before prices get too high Check it out by going here now Cabaletta Bio Earnings HeadlinesCabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measuresDecember 10, 2024 | finance.yahoo.comCabaletta Bio Presents Positive Data On CABA-201 At ACR Convergence 2024November 28, 2024 | nasdaq.comDeFi Coin on Verge of Breakout![FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off! December 18, 2024 | Crypto 101 Media (Ad)Cabaletta Bio to Participate in Upcoming Investor Conferences in DecemberNovember 26, 2024 | markets.businessinsider.comCabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024November 22, 2024 | msn.comCabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024November 20, 2024 | nasdaq.comSee More Cabaletta Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cabaletta Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cabaletta Bio and other key companies, straight to your email. Email Address About Cabaletta BioCabaletta Bio (NASDAQ:CABA), a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.View Cabaletta Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
